Granules India Limited

GRANULES

INE101D01020

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:49 2024-04-23 am EDT			5-day change	1st Jan Change
414.3 ^INR	-0.10%		+1.25%	+2.20%

Apr. 15	Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit	MT
Apr. 03	Granules India Unit Gets VAI Status for Virginia Facility	MT

Granules India Limited Announces Jyothi Prasad Resigned from the Board of Directors of the Company with Immediate Effect

October 06, 2021 at 05:49 am EDT

Granules India Limited announced that Mrs. Jyothi Prasad Independent Director of the Company has vide resignation letter dated October 06, 2021 resigned from the Board of Directors of the Company with immediate effect, on account of personal reasons.

Latest news about Granules India Limited

Granules India Gets Zero Observation from US FDA After Inspection of Visakhapatnam, India Unit	Apr. 15	MT
Granules India Unit Gets VAI Status for Virginia Facility	Apr. 03	MT
Granules India Limited Announces Appointment of Directors	Apr. 02	CI
Granules India Limited Announces Cessation of Arun Rao Akinepally as Independent Director	Mar. 29	CI
Granules India Limited Announces Appointment of Sethu Madhavan Sankaran as Senior Vice President - Api Manufacturing & Operations	Mar. 29	CI
Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer	Mar. 11	CI
Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing	Mar. 05	CI
Transcript : Granules India Limited, Q3 2024 Earnings Call, Jan 23, 2024	Jan. 23
Paracetamol maker Granules India posts marginal rise in Q3 profit	Jan. 23	RE
Granules India's Posts Gains in Fiscal Q3 Consolidated Net Profit	Jan. 23	MT
Granules India Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Jan. 23	CI
Granules Pharmaceuticals Unit's Virginia Facility Gets Five Observations from US FDA	Dec. 18	MT
Granules India Gets US FDA Nod for Pantoprazole Sodium Delayed-Release Tablets	Dec. 13	MT
Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets	Dec. 13	CI
Granules India Arm Gets US FDA Nod for Sildenafil for Oral Suspension	Dec. 03	MT
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand	Nov. 09	RE
Transcript : Granules India Limited, Q2 2024 Earnings Call, Nov 09, 2023	Nov. 09
Granules India Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 09	CI
Granules India Gets US FDA's Approval for Generic Drug for GERD Symptoms	23-10-19	MT
Granules India Limited Receives ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules	23-10-19	CI
Indian paracetamol maker Valiant Laboratories lists at 16% premium	23-10-06	RE
Granules India Gets US FDA Nod for Hypertension Treatment Drug	23-10-01	MT
Granules India Limited Announces the US Food & Drug Administration Approval of its Abbreviated New Drug Application for Losartan Potassium and Hydrochlorothiazide Tablets USP	23-09-30	CI
Granules India's Telangana Facility Gets Accreditation from Japanese Regulator	23-08-25	MT
Granules India Limited Receives Approval from Brazilian Health Regulatory Agency	23-08-24	CI

Chart Granules India Limited

Duration

Period

More charts

Company Profile

Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceuticals products segment. Its geographical segments include within India and outside India. The Company has its presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It has over eight manufacturing facilities, approximately seven of which are located in India and one in the United States. The Company sells its products in the global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific and India. The Companyâs wholly owned subsidiaries include Granules USA Inc, Granules Pharmaceuticals Inc, Granules Europe Limited and Granules Lifesciences Private Limited.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Granules India Limited

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

414.3 INR

Average target price

483.4 INR

Spread / Average Target

+16.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GRANULES INDIA LIMITED	+2.20%	1.21B
ELI LILLY AND COMPANY	+27.17%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.16%	359B
MERCK & CO., INC.	+16.50%	322B
ABBVIE INC.	+9.80%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.84%	149B

Other Pharmaceuticals